Andrzej Mackiewicz Selected Research

Silk

5/2021	Application of a three-dimensional (3D) breast cancer model to study macrophage polarization.
1/2021	MS1-type bioengineered spider silk nanoparticles do not exhibit toxicity in an in vivo mouse model.
1/2021	Hyperthermia treatment of cancer cells by the application of targeted silk/iron oxide composite spheres.
12/2020	Functionalized silk spheres selectively and effectively deliver a cytotoxic drug to targeted cancer cells in vivo.
3/2020	Drug affinity and targeted delivery: double functionalization of silk spheres for controlled doxorubicin delivery into Her2-positive cancer cells.
1/2020	Implementation of a dynamic culture condition to the heterotypic 3D breast cancer model.
1/2019	Cellular uptake, intracellular distribution and degradation of Her2-targeting silk nanospheres.
12/2018	Optimization of spider silk sphere formation processing conditions to obtain carriers with controlled characteristics.
1/2018	Heterotypic breast cancer model based on a silk fibroin scaffold to study the tumor microenvironment.
4/2017	Blending two bioengineered spider silks to develop cancer targeting spheres.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andrzej Mackiewicz Research Topics

Disease

48	Neoplasms (Cancer) 06/2021 - 04/2002
39	Melanoma (Melanoma, Malignant) 03/2021 - 01/2002
9	Breast Neoplasms (Breast Cancer) 05/2021 - 07/2004
7	Squamous Cell Carcinoma of Head and Neck 09/2021 - 11/2018
3	Carcinogenesis 03/2021 - 01/2017
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 09/2020 - 01/2015
2	Pain (Aches) 12/2021 - 10/2015
2	Hyperthermia 01/2021 - 01/2019
2	Neoplasm Metastasis (Metastasis) 01/2019 - 01/2017
2	Keratoacanthoma 01/2018 - 01/2015
2	Neutropenia 01/2016 - 08/2003
2	Disease Progression 10/2015 - 01/2007
1	Endometriosis 12/2021
1	Immune System Diseases (Immune Disorders) 12/2021
1	Infertility (Sterility) 12/2021
1	Head and Neck Neoplasms (Head and Neck Cancer) 09/2021
1	Vesicular Stomatitis 12/2020
1	Hereditary Nonpolyposis Colorectal Neoplasms (Hereditary Nonpolyposis Colorectal Cancer) 10/2020
1	Infections 09/2020
1	Papillomavirus Infections 09/2020
1	Psoriasis (Pustulosis Palmaris et Plantaris) 09/2020
1	Hypertension (High Blood Pressure) 01/2018
1	Arthralgia (Joint Pain) 01/2018
1	Exanthema (Rash) 01/2018
1	Wounds and Injuries (Trauma) 10/2017
1	Hypophysitis 01/2017
1	Colitis 01/2017
1	Anemia 01/2016
1	Thrombocytopenia (Thrombopenia) 01/2016

Drug/Important Bio-Agent (IBA)

15	VaccinesIBA 07/2020 - 01/2003
13	Silk FDA Link 05/2021 - 08/2014
10	Biomarkers (Surrogate Marker)IBA 09/2021 - 02/2015
9	Pharmaceutical PreparationsIBA 01/2021 - 01/2003
7	Proteins (Proteins, Gene)FDA Link 09/2021 - 01/2002
7	VemurafenibIBA 12/2019 - 01/2012
6	AntigensIBA 01/2021 - 01/2003
6	Long Noncoding RNAIBA 09/2020 - 11/2018
5	Cancer VaccinesIBA 03/2020 - 01/2002
5	IpilimumabIBA 01/2020 - 01/2012
5	dabrafenibIBA 01/2019 - 01/2012
5	trametinibIBA 01/2019 - 01/2012
5	CytokinesIBA 01/2016 - 01/2003
4	Peptides (Polypeptides)IBA 03/2020 - 01/2018
4	Interleukin-12 (IL 12)IBA 05/2008 - 08/2003
3	RNA (Ribonucleic Acid)IBA 09/2020 - 01/2017
3	AntibodiesIBA 09/2020 - 10/2003
3	Docetaxel (Taxotere)FDA Link 09/2020 - 07/2008
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2019 - 01/2017
3	Interleukin-6 (Interleukin 6)IBA 01/2018 - 01/2002
2	Biological ProductsIBA 09/2021 - 01/2019
2	Melanins (Melanin)IBA 06/2021 - 03/2021
2	Monophenol Monooxygenase (Tyrosinase)IBA 01/2021 - 05/2019
2	ErbB Receptors (EGF Receptor)IBA 01/2021 - 10/2017
2	Doxorubicin (Adriamycin)FDA LinkGeneric 12/2020 - 03/2020
2	Epithelial Cell Adhesion MoleculeIBA 10/2020 - 01/2015
2	Immune Checkpoint InhibitorsIBA 09/2020 - 01/2017
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2019 - 01/2017
2	LigandsIBA 01/2019 - 01/2003
2	Alanine Transaminase (SGPT)IBA 01/2018 - 01/2017
2	MicroRNAs (MicroRNA)IBA 10/2017 - 01/2014
2	3' Untranslated Regions (3' UTR)IBA 01/2015 - 01/2007
2	DNA (Deoxyribonucleic Acid)IBA 01/2013 - 04/2002
2	Antineoplastic Agents (Antineoplastics)IBA 07/2008 - 01/2003
2	Interleukin-15 (Interleukin 15)IBA 05/2008 - 04/2004
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/2008 - 01/2003
2	CaspasesIBA 10/2005 - 01/2003
2	InterleukinsIBA 06/2004 - 08/2003
1	Therapeutic UsesIBA 12/2021
1	Immunologic Factors (Immunomodulators)IBA 12/2021
1	Glucose (Dextrose)FDA LinkGeneric 06/2021
1	Phosphotransferases (Kinase)IBA 03/2021
1	ferric oxide (iron oxide)IBA 01/2021
1	Antiviral Agents (Antivirals)IBA 12/2020
1	Cisplatin (Platino)FDA LinkGeneric 09/2020
1	Fluorouracil (Carac)FDA LinkGeneric 09/2020
1	PolymersIBA 03/2020
1	ChromatinIBA 01/2020
1	Tripartite Motif ProteinsIBA 01/2020
1	Melanoma-Specific AntigensIBA 05/2019
1	MART-1 AntigenIBA 05/2019
1	Glycoproteins (Glycoprotein)IBA 05/2019
1	Contrast MediaIBA 01/2019
1	Fibroins (Fibroin)IBA 01/2018
1	HLA-A*02:01 antigenIBA 01/2018
1	Complementary DNA (cDNA)IBA 01/2018
1	Aldehyde DehydrogenaseIBA 01/2018
1	IsoenzymesIBA 01/2018
1	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 01/2018
1	Phenobarbital (Luminal)FDA Link 10/2017
1	Tripartite Motif-Containing Protein 28IBA 01/2017
1	Small Interfering RNA (siRNA)IBA 01/2017
1	OligonucleotidesIBA 01/2017

Therapy/Procedure

27	Therapeutics 09/2021 - 01/2002
11	Immunotherapy 12/2021 - 01/2003
4	Drug Therapy (Chemotherapy) 12/2020 - 01/2002
4	Radiotherapy 10/2017 - 01/2002
4	Injections 03/2015 - 08/2003
1	Lasers (Laser) 06/2021
1	Segmental Mastectomy (Lumpectomy) 10/2017
1	Intravenous Infusions 01/2017